FDA approves nivolumab for adjuvant treatment of Stage IIB/C …
WEBOn October 13, 2023, the Food and Drug Administration approved nivolumab (Opdivo, Bristol-Myers Squibb Company) for the adjuvant treatment of completely resected Stage IIB/C melanoma in patients...
FDA approves nivolumab in combination with cisplatin and …
WEBOn March 6, 2024, the Food and Drug Administration approved nivolumab (Opdivo, Bristol-Myers Squibb Company) in combination with cisplatin and gemcitabine for first-line treatment of adult...
Subcutaneous Versus IV Nivolumab for Kidney Cancer
WEBMar 13, 2024 · For people with advanced kidney cancer, an injectable form of nivolumab (Opdivo) is a suitable alternative to the original intravenous form, early results from a clinical trial have shown. Experts say the injectable form makes the treatment quicker and easier for patients to receive.
Perioperative Nivolumab and Chemotherapy in Stage III …
WEBJun 28, 2023 · In patients with resectable stage IIIA or IIIB NSCLC, perioperative treatment with nivolumab plus chemotherapy resulted in a higher percentage of patients with a pathological complete response...
Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial ...
WEBJun 2, 2021 · Disease-free survival was significantly longer with adjuvant nivolumab than with placebo among patients with high-risk muscle-invasive urothelial carcinoma after radical surgery with curative...
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III …
WEBJun 2, 2024 · Among patients with resectable, macroscopic stage III melanoma, neoadjuvant ipilimumab plus nivolumab followed by surgery and response-driven adjuvant therapy resulted in longer event-free ...
Bristol Myers Squibb - U.S. Food and Drug Administration Accepts ...
WEBMay 6, 2024 · Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor. The FDA assigned a target action date of February 28, 2025.
U.S. Food and Drug Administration Approves Opdivo®(nivolumab…
WEBOct 13, 2023 · PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo ® (nivolumab) was approved by the U.S. Food and Drug Administration (FDA) for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected stage IIB or IIC melanoma, expanding upon …
Nivolumab and Relatlimab for Advanced Melanoma - NCI
WEBJan 6, 2022 · People with advanced melanoma treated with two immunotherapy drugs—nivolumab (Opdivo) and a new drug called relatlimab, which targets a protein called LAG-3—lived longer without their cancer getting worse than those treated only with nivolumab, according to results from a large clinical trial.
Subcutaneous nivolumab as effective as IV for renal cell …
WEBJan 29, 2024 · Subcutaneous injection of the immunotherapy nivolumab (brand name Opdivo) is noninferior to intravenous delivery and dramatically reduces treatment time in patients with renal cell carcinoma, as...